BR112021011107A2 - Anticorpos para o fator de complemento humano c2b e métodos de uso - Google Patents

Anticorpos para o fator de complemento humano c2b e métodos de uso

Info

Publication number
BR112021011107A2
BR112021011107A2 BR112021011107A BR112021011107A BR112021011107A2 BR 112021011107 A2 BR112021011107 A2 BR 112021011107A2 BR 112021011107 A BR112021011107 A BR 112021011107A BR 112021011107 A BR112021011107 A BR 112021011107A BR 112021011107 A2 BR112021011107 A2 BR 112021011107A2
Authority
BR
Brazil
Prior art keywords
antibodies
antigen
binding fragments
methods
human
Prior art date
Application number
BR112021011107A
Other languages
English (en)
Inventor
Christophe Blanchetot
De Haard Hans
Original Assignee
Argenx Bvba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Argenx Bvba filed Critical Argenx Bvba
Publication of BR112021011107A2 publication Critical patent/BR112021011107A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

anticorpos para o fator de complemento humano c2b e métodos de uso. são providos anticorpos e fragmentos de ligação ao antígeno dos mesmos que se ligam especificamente ao fator do complemento humano c2 e são capazes de inibir a ativação das vias clássica e da lectina do sistema do complemento. os anticorpos e o fragmento de ligação ao antígeno apresentam capacidade de fabricação, farmacocinética e varredura de antígeno melhoradas. também são providas composições farmacêuticas que compreendem os anticorpos e fragmentos de ligação ao antígeno, ácidos nucleicos e vetores que codificam os anticorpos e fragmentos de ligação ao antígeno, células hospedeiras que compreendem os ácidos nucleicos ou vetores, e métodos de produção e uso dos anticorpos e fragmentos de ligação ao antígeno. os anticorpos e fragmentos de ligação ao antígeno podem ser usados para inibir a via clássica de ativação do complemento em um indivíduo, por exemplo, um humano. os anticorpos e fragmentos de ligação ao antígeno também podem ser usados para inibir a via da lectina de ativação do complemento em um indivíduo, por exemplo, um humano.
BR112021011107A 2018-12-13 2019-12-13 Anticorpos para o fator de complemento humano c2b e métodos de uso BR112021011107A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862779102P 2018-12-13 2018-12-13
PCT/IB2019/060802 WO2020121282A1 (en) 2018-12-13 2019-12-13 Antibodies to human complement factor c2b and methods of use

Publications (1)

Publication Number Publication Date
BR112021011107A2 true BR112021011107A2 (pt) 2021-12-14

Family

ID=69143627

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021011107A BR112021011107A2 (pt) 2018-12-13 2019-12-13 Anticorpos para o fator de complemento humano c2b e métodos de uso

Country Status (13)

Country Link
US (4) US11161900B2 (pt)
EP (2) EP3893924A1 (pt)
JP (2) JP7110491B2 (pt)
KR (1) KR20210100688A (pt)
CN (1) CN113260375A (pt)
AU (2) AU2019397614B2 (pt)
BR (1) BR112021011107A2 (pt)
CA (1) CA3119655A1 (pt)
EA (1) EA202191658A1 (pt)
IL (1) IL283916A (pt)
MX (1) MX2021006864A (pt)
SG (1) SG11202105195PA (pt)
WO (1) WO2020121282A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113260375A (zh) 2018-12-13 2021-08-13 阿尔金克斯有限公司 针对人补体因子C2b的抗体及使用方法
GB2584105B (en) * 2019-05-21 2023-08-02 Argenx Bvba Methods of treating neuropathy

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1265929E (pt) 2000-03-23 2009-10-15 Genentech Inc Inibidores anti-c2/c2a de activação complementar
US8501705B2 (en) 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
US8163881B2 (en) 2005-05-31 2012-04-24 The Board Of Regents Of The University Of Texas System Immunoglobulin molecules with improved characteristics
EP2010214A4 (en) 2006-04-10 2010-06-16 Abbott Biotech Ltd USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
MX2008015524A (es) * 2006-06-12 2009-01-13 Trubion Pharmaceuticals Inc Proteinas de union multivalentes monocatenarias con funcion efectora.
ES2831325T3 (es) 2006-10-10 2021-06-08 Regenesance B V Inhibición del complemento para una mejor regeneración de los nervios
KR20150002874A (ko) * 2008-05-05 2015-01-07 노비뮨 에스 에이 항-ｉｌ-１７ａ／ｉｌ-１７ｆ 교차-반응성 항체 및 그의 사용 방법
WO2010056399A1 (en) 2008-11-17 2010-05-20 Incode Biopharmaceutics, Inc. Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors
JP2013533243A (ja) * 2010-06-22 2013-08-22 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレート 補体成分３のＣ３ｄ断片に対する抗体
CA3025762C (en) * 2011-05-04 2021-11-09 Omeros Corporation Compositions for inhibiting masp-2 dependent complement activation
JP6249949B2 (ja) 2011-09-07 2017-12-20 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 薬物動態特性の改善されたコンプスタチンアナログ
WO2014096958A1 (en) 2012-11-02 2014-06-26 Academisch Medisch Centrum Inosine monophosphate and salts thereof for use in the treatment of complement-related disorders
CA2889197A1 (en) * 2012-11-02 2014-05-08 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
WO2014186622A2 (en) 2013-05-15 2014-11-20 Annexon, Inc. Methods of treatment for guillain-barre syndrome
DK3725803T3 (da) * 2013-05-23 2022-03-07 Broteio Pharma B V Bindingsmolekyler som binder human komplementfaktor C2b, og anvendelser deraf
CA2859114A1 (en) 2013-08-29 2015-02-28 International Automotive Components Group North America, Inc. Formed articles comprising carbon and natural fibers, methods of manufacture and use thereof
PL3052192T3 (pl) * 2013-10-02 2021-04-06 Medimmune, Llc Przeciwciała neutralizujące przeciwko grypie A i ich zastosowania
RU2020111211A (ru) * 2013-10-17 2021-11-08 Омерос Корпорейшн Способы лечения состояний, ассоциированных с masp-2-зависимой активацией комплемента
BR112016013148B1 (pt) 2013-12-12 2024-02-27 Alnylam Pharmaceuticals, Inc ÁCIDO RIBONUCLEICO DE FITA DUPLA (dsRNA) PARA INIBIÇÃO DA EXPRESSÃO DO FATOR B DO COMPLEMENTO (CFB) EM UMA CÉLULA, COMPOSIÇÃO FARMACÊUTICA PARA INIBIÇÃO DA EXPRESSÃO DE UM GENE DO FATOR B DO COMPLEMENTO, SEU USO, E MÉTODO IN VITRO DE INIBIÇÃO DA EXPRESSÃO DO FATOR B DO COMPLEMENTO (CFB) EM UMA CÉLULA
KR102626877B1 (ko) 2014-11-05 2024-01-19 애넥슨, 인코포레이티드 인간화 항-보체 인자 c1q 항체 및 이의 용도
US20180327506A1 (en) * 2015-11-19 2018-11-15 Abbvie Stemcentrx Llc Novel anti-emr2 antibodies and methods of use
WO2017091719A1 (en) 2015-11-24 2017-06-01 Annexon, Inc. Anti-complement factor c1q fab fragments and uses thereof
WO2017132259A1 (en) * 2016-01-25 2017-08-03 Shire Human Genetic Therapies, Inc. Anti-c5 antibodies with enhanced ph switch
WO2017129737A1 (en) 2016-01-27 2017-08-03 Csl Behring Recombinant Facility Ag Recombinant igg fc multimers
WO2017196960A1 (en) 2016-05-10 2017-11-16 Annexon, Inc. Anti-complement factor c4/c4b antibodies and uses thereof
WO2018107109A1 (en) * 2016-12-09 2018-06-14 Abbvie Stemcentrx Llc Novel anti-kremen2 antibodies and methods of use
TW201842931A (zh) 2017-03-14 2018-12-16 美商生物維瑞提夫美國公司 用於治療補體介導之疾病及病症之方法
JP2020517242A (ja) * 2017-04-21 2020-06-18 スターテン・バイオテクノロジー・ベー・フェー 抗ＡｐｏＣ３抗体およびその使用方法
SG11202002940QA (en) 2017-11-01 2020-04-29 Alnylam Pharmaceuticals Inc Complement component c3 irna compositions and methods of use thereof
CN113260375A (zh) * 2018-12-13 2021-08-13 阿尔金克斯有限公司 针对人补体因子C2b的抗体及使用方法

Also Published As

Publication number Publication date
WO2020121282A1 (en) 2020-06-18
MX2021006864A (es) 2021-07-02
EA202191658A1 (ru) 2021-11-03
US20220267424A1 (en) 2022-08-25
US20220119509A1 (en) 2022-04-21
US20200239554A1 (en) 2020-07-30
SG11202105195PA (en) 2021-06-29
IL283916A (en) 2021-07-29
KR20210100688A (ko) 2021-08-17
AU2019397614A1 (en) 2021-06-03
US11591386B2 (en) 2023-02-28
JP7110491B2 (ja) 2022-08-01
CA3119655A1 (en) 2020-06-18
US20240002484A1 (en) 2024-01-04
CN113260375A (zh) 2021-08-13
JP2022160479A (ja) 2022-10-19
US11161900B2 (en) 2021-11-02
US11708403B2 (en) 2023-07-25
AU2019397614B2 (en) 2022-09-15
EP3893924A1 (en) 2021-10-20
JP2022512223A (ja) 2022-02-02
AU2022287637A1 (en) 2023-02-02
EP4375297A2 (en) 2024-05-29

Similar Documents

Publication Publication Date Title
BR112019008634A2 (pt) anticorpos anti-pd-l1 e variantes
BR112019005129A2 (pt) anticorpos anti-pd-1
BR112018072485A2 (pt) proteínas de ligação biespecíficas e usos das mesmas
BR112018014028A2 (pt) anticorpos monoclonais anti-cd47 humanizados, de camundongo ou quimérico
BR112017007093A2 (pt) composições e métodos de uso para aumento da resposta imune e terapia do câncer
BR112018007318A2 (pt) anticorpo isolado ou fragmento de ligação a antígeno, composição farmacêutica, e, métodos para tratar uma doença ou condição.
BR112018015545A2 (pt) tratamentos de câncer do útero
BR112017012944A2 (pt) ?anticorpo, composição farmacêutica, molécula de polinucleotídeo isolada, vetor, célula, e, método para prevenção, tratamento ou melhoria de pelo menos um sintoma de infecção de influenza?
EA200870129A1 (ru) Человеческие антитела против il-23, композиции, способы и применение
BR112016013347A8 (pt) anticorpo monoclonal humano neutralizante anti-il-33,composição farmacêutica,inibidor da expressão de citocinas,epitopo,molécula de ácido nucleico,vetor,célula hospedeira,método de produção e uso dos mesmos.
BR112022000216A2 (pt) Anticorpos direcionados a dll3 e usos dos mesmos
BR112012025568A2 (pt) proteínas de ligação ao tnf-<244>.
BR112016027805A2 (pt) receptores de células t do anti-papilomavírus humano 16 e7
BRPI0606790A2 (pt) anticorpo humano isolado ou porção de ligação de antìgeno do mesmo, polipeptìdeo isolado, composição, ácido nucleico isolado, vetor de expressão célula hospedeira, vacina contra a raiva, kit, uso de um anticorpo monoclonal humano isolado ou porção de ligação de antìgeno do mesmo, ou de uma quantidade eficaz de uma composição, método para identificar um anticorpo ou um fragmento do mesmo, anticorpo ou fragmento do mesmo, anticorpo ou fragmento do mesmo,e, glicoproteìna.
BR112018074869A2 (pt) anticorpos antagonistas que ligam t ao tgfb1, tgfb2 e ao tgfb3 humanos e seu uso para o tratamento de fibrose pulmonar
BR112017027702A2 (pt) anticorpos antirreceptor do fator de crescimento endotelial vascular 2 (vegfr2)
BR112012013915A8 (pt) anticorpos anti-c4. 4a e usos dos mesmos
BR112021011107A2 (pt) Anticorpos para o fator de complemento humano c2b e métodos de uso
BR112018006006A2 (pt) receptores de antígeno, cadeias peptídicas, células recombinantes, métodos para produzir uma célula que expressa um receptor de antígeno e para o tratamento de uma doença, ácidos nucleicos e composição farmacêutica
BR112021026133A2 (pt) Anticorpo anti-cd24 e usos do mesmo
BR112021016398A2 (pt) Anticorpos cd33 e métodos de uso dos mesmos para tratar o câncer
BR112022012474A2 (pt) Anticorpo anti-lilrb1, fragmento de ligação ao antígeno do mesmo, composição farmacêutica que compreende os mesmos, uso do dito anticorpo para tratar ou prevenir um câncer, método de preparar o dito anticorpo, molécula de ácido nucleico e vetor e célula recombinantes.
BR112021016791A2 (pt) Proteínas de ligação de antígenos que se ligam a bcma
Goswami et al. AVA-NP-695 selectively inhibits ENPP1 to activate STING pathway and abrogate tumor metastasis in 4T1 breast cancer syngeneic mouse model
BR112017022205A2 (pt) anticorpo anti-vegfr2 humano para terapia de câncer antiangiogênica e objetivada